Sabby Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Sabby Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-165,529	Closed	-$1.71M	–	304
2015 Q4	$1.71M	Buy	165,529 +79,134	+92%	+$787K	0.09%	137
2015 Q3	$985K	Buy	+86,395	New	+$1.15M	0.04%	238
2014 Q3	–	Sell	-77,987	Closed	-$994K	–	267
2014 Q2	$994K	Buy	+77,987	New	+$759K	0.04%	153

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's BCRX Position: Q1 2016 in Review

Sabby Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2016, closing a stake of 165,529 shares — an estimated $1.71M sold.

Sabby Management first reported a position in BCRX in Q2 2014 and held it in 3 quarters. The position peaked at $1.71M in Q4 2015. 109 funds tracked by Wall St. Rank hold BCRX as of Q1 2016.

Sabby Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Sabby Management sold 165,529 BioCryst Pharmaceuticals shares in Q1 2016, an estimated $1.71M.
Sabby Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 3 quarters.
Sabby Management's BioCryst Pharmaceuticals position peaked at $1.71M in Q4 2015.
109 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2016.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.